Business Context and Reporting Period
This Form 8-K is a current report filed by ReShape Lifesciences Inc. (not Vyome Holdings, Inc.) on May 15, 2023. The filing serves to announce the company's financial results for the three-month period ended March 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol RSLS.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text provided.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. It only confirms the issuance of a press release containing the Q1 2023 results.
Guidance, Outlook, and Risks
The filing includes a standard legal disclaimer stating that the information furnished pursuant to Item 2.02 and in Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and shall not be subject to the liabilities of that section. No specific guidance, outlook, or risk factors are detailed in the provided text.
Investor Verification Checklist
- Verify the correct registrant name: The filing is for ReShape Lifesciences Inc., not Vyome Holdings, Inc.
- Review Exhibit 99.1 (Press Release dated May 15, 2023) for actual financial figures, as they are absent from the 8-K cover text.
- Confirm the reporting period is the three months ended March 31, 2023.
- Note that the financial data in the press release is "furnished" and not "filed" under Section 18 of the Exchange Act.